Optune Lua, the brand name for Novocure’s tumor treating fields therapy for malignant mesothelioma, continues adding more hospitals to its partner list.
In June, three more hospitals got approval from their Internal Review Boards to offer patients this therapy. The three are:
- Onslow Memorial Hospital (Jacksonville, N.C.)
- Alabama Oncology (Birmingham)
- Bon Secours Cancer Institute (Mechanicsville, Virginia)
This brings the total number of hospitals in the United States with Optune Lua to 104. Some of them are separate locations for the same health system, such as Ochsner Hospital’s two locations in Louisiana.
Optune Lua is the branded device delivering tumor treating fields for cancer. It received approval from the U.S. Food and Drug Administration in May 2019 for malignant pleural mesothelioma. Optune Lua is only for unresectable cases of the cancer and must be used with a chemotherapy regimen of cisplatin and pemetrexed.
More than 30 states have a hospital offering this unique therapy. Some of the top-ranked mesothelioma cancer centers offering Optune Lua are:
- University of Miami Health System
- Loyola University Medical Center
- Cleveland Clinic
- University of Maryland Medical Center
- Oregon Health and Sciences Center
Optune Lua sends electromagnetic waves through the patient’s body. These waves disrupt cancer cell replication and halt the growth of tumors. Optune Lua has a 97% disease‑response rate, meaning there’s a positive reaction for the patient to this therapy.
If you are seeking medical care for your mesothelioma cancer, we can help. Contact our registered nurse, Karen Ritter, at email@example.com. She can help you start Optune Lua therapy or another treatment to begin fighting your tumors.
Sources & Author